These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23210647)

  • 1. Biomarker assay development and validation for large molecules in bioanalysis: what are the challenges and how are they overcome?
    Stevenson LF
    Bioanalysis; 2012 Nov; 4(22):2657-9. PubMed ID: 23210647
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
    Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
    J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Would you prefer multiple reaction monitoring or antibodies with your biomarker validation?
    Issaq HJ; Veenstra TD
    Expert Rev Proteomics; 2008 Dec; 5(6):761-3. PubMed ID: 19086854
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiplex assays for biomarker research and clinical application: translational science coming of age.
    Fu Q; Schoenhoff FS; Savage WJ; Zhang P; Van Eyk JE
    Proteomics Clin Appl; 2010 Mar; 4(3):271-84. PubMed ID: 21137048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex immunoassays: an invaluable tool for biomarker discovery and validation.
    Lehr S
    Arch Physiol Biochem; 2012 Oct; 118(4):191. PubMed ID: 22747464
    [No Abstract]   [Full Text] [Related]  

  • 6. Interference in immunoassays to support therapeutic antibody development in preclinical and clinical studies.
    Schwickart M; Vainshtein I; Lee R; Schneider A; Liang M
    Bioanalysis; 2014; 6(14):1939-51. PubMed ID: 24806787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations on biomarker bioanalytical method validation by GCC.
    Hougton R; Gouty D; Allinson J; Green R; Losauro M; Lowes S; LeLacheur R; Garofolo F; Couerbe P; Bronner S; Struwe P; Schiebl C; Sangster T; Pattison C; Islam R; Garofolo W; Pawula M; Buonarati M; Hayes R; Cameron M; Nicholson R; Harman J; Wieling J; De Boer T; Reuschel S; Cojocaru L; Harter T; Malone M; Nowatzke W
    Bioanalysis; 2012 Oct; 4(20):2439-46. PubMed ID: 23157353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays.
    Rai AJ
    Expert Rev Mol Diagn; 2007 Sep; 7(5):545-53. PubMed ID: 17892363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-binding assays: risk of using a platform supported by a single vendor.
    Yohrling J
    Bioanalysis; 2009 Jun; 1(3):629-36. PubMed ID: 21083158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.
    Lee JW; Salimi-Moosavi H
    Bioanalysis; 2012 Oct; 4(20):2513-23. PubMed ID: 23157359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid immunoaffinity--mass spectrometric methods for efficient protein biomarker verification in pharmaceutical development.
    Ackermann BL
    Bioanalysis; 2009 May; 1(2):265-8. PubMed ID: 21083162
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid development of novel protein biomarkers using real-time immunoassays.
    Houle JF
    Bioanalysis; 2010 Jun; 2(6):991-3. PubMed ID: 21083200
    [No Abstract]   [Full Text] [Related]  

  • 13. Microfluidic homo- and hetero-geneous immunoassays: a tool to accelerate protein biomarker development.
    Karns K; Herr AE
    Bioanalysis; 2011 Oct; 3(19):2161-5. PubMed ID: 21985410
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxytocin is not a valid biomarker when measured in saliva by immunoassay.
    Horvat-Gordon M; Granger DA; Schwartz EB; Nelson VJ; Kivlighan KT
    Physiol Behav; 2005 Mar; 84(3):445-8. PubMed ID: 15763582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.
    Bowsher RR; Sailstad JM
    J Pharm Biomed Anal; 2008 Dec; 48(5):1282-9. PubMed ID: 18977625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioanalytical interferences in immunoassays for antibody biotherapeutics.
    Pendley C; Shankar G
    Bioanalysis; 2011 Apr; 3(7):703-6. PubMed ID: 21452985
    [No Abstract]   [Full Text] [Related]  

  • 17. Mass spectrometry-based protein assays for in vitro diagnostic testing.
    Nedelkov D
    Expert Rev Mol Diagn; 2012 Apr; 12(3):235-9. PubMed ID: 22468814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations on ISR in multi analyte assays, QA/bioanalytical consultants and GCP by Global CRO Council for Bioanalysis (GCC).
    Sangster T; Maltas J; Struwe P; Hillier J; Boterman M; Doig M; Breda M; Garofolo F; Caturla MC; Couerbe P; Schiebl C; Pattison C; Goodwin L; Segers R; Garofolo W; Folguera L; Zimmer D; Zimmerman T; Pawula M; Tang D; Cox C; Bigogno C; Schoutsen D; de Boer T; Green R; Houghton R; Sable R; Siethoff C; Harter T; Best S;
    Bioanalysis; 2012 Jul; 4(14):1723-30. PubMed ID: 22877218
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of Dolichos biflorus in immunoassay detection of kidney collecting duct biomarkers.
    Sourial S; Searchfield L; Schuppe-Koistinen I; Betton GR; Riccardi D; Price SA
    Biomarkers; 2010 Aug; 15(5):424-35. PubMed ID: 20491521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long and difficult road to the diagnostic market: protein microarrays.
    Joos TO; Berger H
    Drug Discov Today; 2006 Nov; 11(21-22):959-61. PubMed ID: 17055403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.